Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 29 clinical trials
Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER)

The aim of this study is to assess the treatment effect of sacubitril valsartan versus conventional therapy for heart failure (HF) in admitted patients due to exacerbation of HF on the N

angiotensin ii receptor antagonists
dyspnea
angiotensin
congestion
valsartan
  • 0 views
  • 05 Jan, 2022
  • 1 location
Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.

% reduction in mortality comparing sacubitril/valsartan with the standard treatment with ACE (angiotensin converting enzyme) inhibitors. In the scenario of chagasic cardiomyopathy, a post hoc analysis of

  • 0 views
  • 15 May, 2021
  • 1 location
The Renin-Angiotensin-Aldosterone System in Adiposity Blood Pressure and Glucose in African Americans

The primary objective is to examine the impact of the Renin-Angiotensin-Aldosterone System (RAAS) blockade with medications (valsartan) or RAAS and neprilysin inhibition (valsartan/sacubitril

type 2 diabetes mellitus
glycosylated hemoglobin
hemoglobin a1c
insulin
tolerance test
  • 284 views
  • 10 Mar, 2021
  • 1 location
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals

hypothesis that by augmenting NP levels using sacubitril/valsartan, among Black Individuals one can improve their metabolic health (as measured by insulin sensitivity & energy expenditure) and help

Accepts healthy volunteers
insulin resistance
insulin
antihypertensive drugs
fasting
  • 0 views
  • 19 Dec, 2021
  • 1 location
Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2

LCZ696, a molecular complex of the angiotensin receptor blocker (ARB) valsartan with an inhibitor of neprilysin (NEP, neutral endopeptidase-24.11) sacubitril improved mortality compared to

angiotensin ii receptor antagonists
valsartan
angiotensin
enalapril
n-terminal pro-bnp
  • 2 views
  • 06 May, 2021
  • 1 location
LCZ696 in Advanced LV Hypertrophy and HFpEF

Patients with advanced LVH and HFpEF will be randomly assigned in open-label fashion to receive LCZ696 titrated to 200 mg twice daily or valsartan titrated to 160 mg twice daily, and will be treated for 24 weeks.

ejection fraction
valsartan
heart failure
body mass index
  • 25 views
  • 16 Jan, 2022
  • 1 location
Angiotensin-Neprilysin Inhibition in Diastolic Dysfunction After AMI

This study examines the effect of Entresto on central hemodynamic parameters during exercise in patients with diastolic dysfunction following acute myocardial infarction. Half of the patients will receive Entresto and the other half will receive placebo.

valsartan
angiotensin
entresto
revascularisation
infarct
  • 0 views
  • 20 Oct, 2021
  • 2 locations
Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

This is a double-blind, randomized, two x two crossover (aprepitant vs placebo) during both initiation of Entresto, LCZ696, (50 mg dose) and at steady-state of Entresto (200 mg bid dose or the highest tolerated dose).

angiotensin ii receptor antagonists
valsartan
angiotensin
potassium
nt-probnp
  • 0 views
  • 09 Dec, 2021
  • 2 locations
Sacubitril/Valsartan Versus Valsartan in Heart Failure With Improved Ejection Fraction

heart muscle contractility, which is represented by the left ventricular ejection fraction (LVEF). Valsartan is an angiotensin II receptor blocker, a major drug class for heart failure. Sacubitril

  • 0 views
  • 28 Aug, 2021
  • 1 location